NURIX THERAPEUTICS
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad ... class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation.
NURIX THERAPEUTICS
Industry:
Biotechnology Health Care Life Science Therapeutics
Founded:
2012-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.nurixtx.com
Total Employee:
251+
Status:
Active
Contact:
415-660-5320
Total Funding:
370.9 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail Google Maps Microsoft Azure DNS Google Google Maps API Google Cloud Apple Mobile Web App Capable
Similar Organizations
Aadi Bioscience
Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.
Acumen Pharmaceuticals
Acumen is developing targeted therapies for the safe and effective treatment of Alzheimer’s Disease and related neurodegenerative diseases.
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
ALung Technologies
ALung Technologies develops medical gas exchange devices for the treatment of acute and chronic respiratory disorders.
ATAI Life Sciences
ATAI Life Sciences develops innovative mental health treatments that address significant unmet medical needs.
Axikin Pharmaceuticals
Axikin Pharmaceuticals develops small molecule therapeutics for severe respiratory, inflammatory and autoimmune diseases.
Better Therapeutics
Better Therapeutics develops prescription software for treating cardiometabolic diseases.
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
CalciMedica
CalciMedica is engaged in the discovery and development of small molecule drugs for the treatment of inflammatory and autoimmune disorders.
Carmell Therapeutics
Carmell develops technology for producing biologically-active plastics from blood plasma for treating bone and connective tissue injuries.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
DiscGenics
Regenerative Cell Therapy for Chronic Back Pain.
EnGeneIC
EnGeneIC develops and commercializes the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells.
ExcepGen
ExcepGen is solving fundamental underlying problems in drug discovery to create a new generation of therapeutics.
Felix Biotechnology
Felix Biotechnology is working to accelerate the deployment of novel biotherapeutics to manage infectious diseases.
Gelifex
Gelifex develops implants for use in relieving pain and restoring motion to patients suffering from degenerative disc disease.
HepaRegeniX
HepaRegeniX is developing drugs for treating acute and chronic liver diseases.
Intercept Pharmaceuticals
Intercept Pharmaceuticals develops small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases.
Kodiak Sciences
Kodiak is designing and developing novel therapies for the treatment of retinal disease.
Life Biosciences
Life Biosciences is a developer of drugs designed to promote longevity and find treatments for age-related diseases.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Mobilion Systems
MOBILion Systems specializes in identifying and analyzing challenging molecules that other instruments so far have failed to detect.
Mogrify
Mogrify® will transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies.
Abliva AB
Abliva develops medicines for the treatment of primary mitochondrial diseases.
Noveome Biotherapeutics
Noveome Biotherapeutics focuses on breakthrough therapies for the regenerative repair of inflamed or damaged tissues.
Nutshell Therapeutics
Inventing small molecule in the realm of drug discovery fostered by protein dynamics.
Ocelot Bio
Ocelot Bio brings new treatment options to patients with severe liver disease.
Rigel Pharmaceuticals
Rigel Pharmaceuticals develops small-molecule drugs for the treatment of autoimmune diseases, cancer and metabolic diseases.
Seranova Bio
Seranova Bio develops companion diagnostics or therapeutics to treat autoimmune disease or other autoantibody-driven diseases.
Signum Biosciences
Signum Biosciences develops small molecule therapeutics derived from its STM platform to modulate signal transduction imbalances.
Twist Bioscience
Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development.
Vanquish Oncology
Vanquish Oncology develops targeted, small-molecule oncology therapeutics for unmet or underserved cancer markets.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Virta Health
Virta delivers a clinically-proven treatment to reverse type 2 diabetes and other chronic metabolic diseases.
Current Advisors List
Board_member
2019-08-01
Board_member
Current Employees Featured
Arthur Weiss Co-Founder @ Nurix Therapeutics
Co-Founder
John Kuriyan Co-Founder @ Nurix Therapeutics
Co-Founder
Michael Rape Co-Founder @ Nurix Therapeutics
Co-Founder
Arthur T. Sands Chief Executive Officer @ Nurix Therapeutics
Chief Executive Officer
2014-09-01
Pierre Beaurang Chief Business Officer @ Nurix Therapeutics
Chief Business Officer
2016-02-01
Cristiana Guiducci Vice President, Immunology and Oncology Research @ Nurix Therapeutics
Vice President, Immunology and Oncology Research
2019-10-01
Christine Ring General Counsel @ Nurix Therapeutics
General Counsel
2019-09-01
Jean Chang Vice President, Program Management and Asset Strategy @ Nurix Therapeutics
Vice President, Program Management and Asset Strategy
2019-11-01
Hans van Houte Chief Financial Officer @ Nurix Therapeutics
Chief Financial Officer
2020-06-01
Gwenn Hansen Senior Vice President, Research @ Nurix Therapeutics
Senior Vice President, Research
2019-07-01
Founder
Stock Details
Investors List
Redmile Group
Redmile Group investment in Private Equity Round - Nurix Therapeutics
Boxer Capital
Boxer Capital investment in Private Equity Round - Nurix Therapeutics
The Column Group
The Column Group investment in Private Equity Round - Nurix Therapeutics
Foresite Capital
Foresite Capital investment in Private Equity Round - Nurix Therapeutics
Third Rock Ventures
Third Rock Ventures investment in Private Equity Round - Nurix Therapeutics
EcoR1 Capital
EcoR1 Capital investment in Private Equity Round - Nurix Therapeutics
Wellington Management
Wellington Management investment in Private Equity Round - Nurix Therapeutics
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Private Equity Round - Nurix Therapeutics
The Column Group
The Column Group investment in Series B - Nurix Therapeutics
Third Rock Ventures
Third Rock Ventures investment in Series B - Nurix Therapeutics
Official Site Inspections
http://www.nurixtx.com Semrush global rank: 1.92 M Semrush visits lastest month: 11.37 K
- Host name: 172.179.197.104.bc.googleusercontent.com
- IP address: 104.197.179.172
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Nurix Therapeutics"
Learn About Us | Nurix - nurixtx.com
Founded on groundbreaking research in E3 ligases, Nurix has evolved into a targeted protein degradation powerhouse, leveraging its experience and expertise to translate the science of …See details»
Nurix | Medicines to Outmatch Disease
6 days ago Discover Nurix Therapeutic's targeted protein degradation platform, combining degraders and DACs to transform cancer and autoimmune disease treatment.See details»
Leadership at Nurix Therapeutics
Hans van Houte has served as Chief Financial Officer of Nurix since June 2020 and has led the company’s finance team since 2015. Mr. van Houte began his biotechnology finance career as …See details»
Nurix Therapeutics - Crunchbase Company Profile
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and …See details»
Investor FAQs | Nurix Therapeutics, Inc. - ir.nurixtx.com
Please reach out to IR@nurixtx.com for any questions regarding investor relations. How do I obtain the latest Nurix Therapeutics’ financial information? Please visit the Financial …See details»
Nurix Therapeutics Outlines 2025 Goals and Objectives for …
6 days ago “2024 was a year of significant advancement in our research and discovery organization,” said Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix. “We not only …See details»
Nurix Therapeutics - LinkedIn
At Nurix Therapeutics, we aim to fundamentally change the way disease is treated using degrader-based medicines. Our journey began with a vision to harness the power of the cell’s …See details»
Nurix Therapeutics, Inc. (NRIX) - Yahoo Finance
See the company profile for Nurix Therapeutics, Inc. (NRIX) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Nurix Therapeutics - Overview, News & Similar companies
Jul 17, 2024 Nurix Therapeutics contact info: Phone number: (415) 660-5320 Website: www.nurixtx.com What does Nurix Therapeutics do? Nurix Therapeutics founded in 2009 and …See details»
Investors - Nurix Therapeutics, Inc.
Contact. 1700 Owens Street, Suite 205 San Francisco, CA 94158. Direct: 415-660-5320 Fax: 415-525-4200. info@nurix-inc.comSee details»
Nurix Therapeutics Expands Its Board of Directors with the …
SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation …See details»
Nurix Therapeutics Outlines 2025 Goals and Objectives for
4 days ago “2024 was a year of significant advancement in our research and discovery organization,” said Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix. “We not only …See details»
Writing medicine’s next chapter - nurixtx.com
At Nurix Therapeutics, we aim to fundamentally change the way disease is treated using degrader-based medicines. Our journey began with a vision to harness the power of the cell’s …See details»
Nurix Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation …See details»
Working At Nurix: Company Overview and Culture - Zippia
Mar 14, 2024 www.nurixtx.com. Organization Type. Public. Nurix, Inc. is primarily engaged in commercial physical and biological research and development on a contract or fee basis. …See details»
Nurix Therapeutics Outlines 2025 Goals and Objectives for …
5 days ago Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic lymphocytic leukemia Expand the development of NX-5948 …See details»
For Investors Landing Page | Nurix - nurixtx.com
Aug 29, 2024 Nurix is a biopharmaceutical company accelerating development of medicines based on targeted protein degradation, the next frontier to outmatch cancer and autoimmune …See details»
Investors - Nurix Therapeutics, Inc.
Jkantor@nurixtx.com: lwolffe@wheelhouselsa.com: Nurix Therapeutics, Inc. Condensed consolidated statements of operations (in thousands, except share and per share amounts) …See details»
Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial …
Oct 11, 2024 Recent Business Highlights . Expanded clinical development of NX-5948: In the third quarter of 2024, Nurix initiated the Phase 1b portion of its ongoing Phase 1a/b clinical trial …See details»
Nurix Therapeutics, Inc. (NRIX) Stock Price, News, Quote & History ...
Find the latest Nurix Therapeutics, Inc. (NRIX) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»